top of page

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purc

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from investors (the “Investors”) for the sale of 10,127,132 of its ordinary shares, for an approximate value of USD 166 million, par value USD 0.01 per share (the “Shares”), at a purchase price of USD 16.41 per Share, or ISK 2,250 per share at foreign exchange rates on February 23, 2024 (the “Transaction”). The Shares are expected to be delivered to the Investors from previously issued treasury shares held by Alvotech’s subsidiary, Alvotech Manco ehf. The Transaction will be made on the Nasdaq Iceland Exchange. Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
LabNews by Corax Consultants LLC. copyright: Corax Consultants LLC

LabNews by Corax Consultants LLC. copyright: Corax Consultants LLC


Aktuelle Beiträge

Alle ansehen

Comments


bottom of page